Zepbound & Mounjaro: Eli Lilly’s "overnight" successes
$Eli Lilly and Co(LLY.US$ At JPM2024, Eli Lilly’s CEO presented this graphic 📸
to emphasize the point that it took decades of work
to get to the 2022 FDA approval of Mounjaro for Type 2 diabetes
and the November 2023 FDA approval of Zepbound for obesity 👏
to emphasize the point that it took decades of work
to get to the 2022 FDA approval of Mounjaro for Type 2 diabetes
and the November 2023 FDA approval of Zepbound for obesity 👏
ℹ️ Tirzepatide, is the active ingredient in Zepbound and Mounjaro
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
venkym : excellent inputs from u